CD274 and cancer: This quality improvement study evaluates trends in the inclusion of people living with HIV in anti–programmed death 1 and anti–programmed death ligand 1 (anti–PD1/PDL1) clinical trials concurrent with ongoing Cancer Therapy Evaluation Program efforts by the National Cancer Institute to promote inclusion of this patient population.